News Article | April 18, 2017
The Global Wellness Summit (GWS) today announced that an all-star lineup of integrative medicine leaders will present at the 2017 conference: Dr. Richard Carmona (former U.S. Surgeon General), Elissa Epel, PhD (telomeres research pioneer, UCSF), Dr. Paul Limburg (Professor of Medicine, Mayo Clinic), Dr. Mehmet Oz (Professor of Surgery, Columbia University and host, “The Dr. Oz Show”), Dr. Kenneth R. Pelletier (Professor of Medicine, University of Arizona and UCSF), Dr. Michael Roizen (Chief Wellness Officer, The Cleveland Clinic) and Dr. Andrew Weil (founder, University of Arizona Center for Integrative Medicine and renowned alternative medicine expert). Together, this heavy-hitter roster of experts has transformed the way the world thinks about both wellness and medicine, leading the charge for more holistic, preventive approaches that - as chronic disease and healthcare costs soar - represent one of the most critical trends in the world today. They span celebrity doctors who have brought the “wellness message” to hundreds of millions of people worldwide to doctors who are spearheading a new focus on wellness and prevention at revered medical institutions like the Mayo and Cleveland Clinics. The 2017 Summit theme is “Living a Well Life”, focusing on how new wellness concepts will impact every aspect of an individual’s life. And these leaders, who impact countless individuals’ lives, will keynote on everything from the latest in mind-body medicine and sleep science to the coming wave of personal biomarker and DNA testing. The 11th-annual conference is being held at The Breakers, Palm Beach, Florida from October 9-11, 2017. "The annual Global Wellness Summit has proven to be the premier convener of health and wellness thought leaders from around the world,” said Richard Carmona, MD, MPH, FACS, and 17th Surgeon General of The United States. “This year’s unprecedented meeting in Florida will define the essential role of wellness in a world desperately in need of health innovation and disruption." “This may be the most influential, inspiring and diverse group of medical-wellness pioneers ever assembled on a conference stage,” noted Susie Ellis, GWS CEO and chairman. “And delegates will have the opportunity to interact with them one-on-one during the many networking sessions, lunches and roundtables where casual discussions take place. It will be unprecedented access, something the Summit is known for.” More on the presenters: Richard H. Carmona, MD, M.P.H., FACS, was the 17th Surgeon General of the United States. He is also a combat decorated U.S. Army Special Forces Veteran and a Distinguished Professor at the University of Arizona, with a wide range of training and experience in healthcare management, clinical care and research. He’s currently the Vice Chairman of Canyon Ranch, President of the Canyon Ranch Institute, and serves as Director on several large, publicly traded corporate boards and several private companies. Elissa Epel, PhD, is Professor at the University of California, San Francisco (UCSF), with a research focus on how chronic psychological stress accelerates biological aging; the interconnections between emotions, eating, metabolism and weight; and the effects of mindfulness. A member of the National Academy of Medicine, she has won many awards for her research. Epel co-wrote (with Nobel Laureate, Elizabeth Blackburn) “The Telomere Effect: The New Science of Living Younger Longer”, a 2017 New York Times bestseller. Paul Limburg, MD, M.P.H., is Professor of Medicine, Mayo Clinic College of Medicine and consultant in the division of gastroenterology and hepatology. He also holds a joint appointment in the division of preventive, occupational and aerospace medicine and serves as medical director for several business units at Mayo Clinic responsible for defining or delivering health and wellbeing expertise within and beyond the organization. Mehmet Oz, MD, is Professor of Surgery at Columbia University and has won seven Daytime Emmy® Awards for “The Dr. Oz Show”. He directs the Complementary Medicine Program at New York Presbyterian Hospital; participates in 50 heart surgeries a year; has authored over 400 publications, including seven New York Times bestsellers; has received numerous patents; and hosts the internationally syndicated “Daily Dose” in 134 radio markets and a newspaper column in 175 global markets. He has received numerous global accolades, from being named one of TIME magazine’s “100 Most Influential People” to a Global Leader of Tomorrow by the World Economic Forum. Kenneth R. Pelletier, PhD, MD, is Clinical Professor of Medicine at the University of Arizona and the University of California, San Francisco. At UCSF, he is Director of the Corporate Health Improvement Program (CHIP), a collaborative research program between CHIP and 15 of the Fortune 500. He is Chairman of the American Health Association; medical and business consultant to high-profile organizations like the U.S. Department of Health and Human Services and the World Health Organization; and has published over 300 professional articles on behavioral and integrative medicine, disease management, worksite interventions, and epigenetics. The author of 13 books, his next, “Change Your Genes, Change Your Life”, will be published this year. Michael Roizen, MD: Since 2008, Dr. Roizen has served as Chief Wellness Officer at Cleveland Clinic, the first such position at a major U.S. healthcare institution. He’s also Chairman of the Wellness Institute at Cleveland Clinic; has published 175+ peer-reviewed scientific papers, 100 textbook chapters, and four medical books; received 13 U.S. (and many foreign) patents; and hosted six PBS specials. His “RealAge” and “YOU” series of books have sold millions of copies, have been translated into 44 languages, and resulted in four #1 New York Times bestsellers (more than any other physician). Andrew Weil, MD, is Founder and Director of (and Clinical Professor of Medicine at) the University of Arizona Center for Integrative Medicine, the leading global effort to develop a comprehensive curriculum in integrative medicine. He is editorial director of the popular website, Dr. Weil.com; has appeared in numerous PBS programs; and is founder of the Weil Foundation, Healthy Lifestyle Brands, and True Food Kitchen restaurants. An internationally recognized expert on medicinal plants, alternative medicine, and medical education reform, he’s authored many scientific articles and 15 popular books - and Oxford University Press is currently producing the Weil Integrative Medicine Library, a series for clinicians in various medical specialties. For more information, contact Beth McGroarty: email@example.com or (+1) 213-300-0107. For info on attending the 2017 Summit: http://www.globalwellnesssummit.com/2017-summit/ About the Global Wellness Summit: The Global Wellness Summit (GWS) is an invitation-only international gathering that brings together leaders and visionaries to positively shape the future of the $3.7 trillion global wellness economy. Held in a different location each year, Summits have taken place in the U.S., Switzerland, Turkey, Bali, India, Morocco, Mexico and Austria. The next will be held at The Breakers, Palm Beach, Florida from Oct. 9-11, 2017.
News Article | April 21, 2017
Receive press releases from Strathmore Who's Who: By Email Dr. Rubin S. Cooper, of Hollis, New York, has recently been recognized as a Lifetime VIP Member of Strathmores Whos Who for his outstanding contributions and achievements in the field of Pediatric Cardiology. Hollis, NY, April 21, 2017 --( Dr. Rubin Cooper is Chief of Pediatric Cardiology at Cohen Children's Medical Center of New York, as well as Director of the Pediatric Cardiovascular Service Line at the Northwell Health System. He is a Professor of Pediatrics at Hofstra Northwell. Prior to Dr. Cooper’s position at Cohen Children's Medical Center, he was Chief of Pediatric Cardiology at the Komansky Children's Hospital at the New York Presbyterian Hospital, Professor of Clinical Pediatrics at the Weill Cornell Medical College, and Adjunct Professor at the Columbia School of Surgeons and Physicians. While at Cornell he occupied the Starr-Starlight Foundation Chair in Pediatric Cardiology. His clinical research interests include adult congenital heart disease, rheumatic fever, and Kawasaki's Disease; major services include medical education and telehealth. Dr. Cooper is a Board Member of the Make-A-Wish Foundation and has worked with Chai Life Line for close to two decades. He was also a Board Member of the American Heart Association, Long Island Chapter. He is a present Board Member of the Corazon-Corazon Foundation. Dr. Cooper is a Harris Fellow of the International Rotary Gift of Life Foundation. About Strathmore’s Who’s Who Strathmore's Who's Who publishes an annual two thousand page hard cover biographical registry, honoring successful individuals in the fields of Business, the Arts and Sciences, Law, Engineering and Government. Based on one's position and lifetime of accomplishments, we honor professional men and women in all academic areas and professions. Inclusion is limited to individuals who have demonstrated leadership and achievement in their occupation, industry or profession. Hollis, NY, April 21, 2017 --( PR.com )-- About Rubin S. CooperDr. Rubin Cooper is Chief of Pediatric Cardiology at Cohen Children's Medical Center of New York, as well as Director of the Pediatric Cardiovascular Service Line at the Northwell Health System. He is a Professor of Pediatrics at Hofstra Northwell. Prior to Dr. Cooper’s position at Cohen Children's Medical Center, he was Chief of Pediatric Cardiology at the Komansky Children's Hospital at the New York Presbyterian Hospital, Professor of Clinical Pediatrics at the Weill Cornell Medical College, and Adjunct Professor at the Columbia School of Surgeons and Physicians. While at Cornell he occupied the Starr-Starlight Foundation Chair in Pediatric Cardiology. His clinical research interests include adult congenital heart disease, rheumatic fever, and Kawasaki's Disease; major services include medical education and telehealth. Dr. Cooper is a Board Member of the Make-A-Wish Foundation and has worked with Chai Life Line for close to two decades. He was also a Board Member of the American Heart Association, Long Island Chapter. He is a present Board Member of the Corazon-Corazon Foundation. Dr. Cooper is a Harris Fellow of the International Rotary Gift of Life Foundation. www.ccmc.northshorelij.com About Strathmore’s Who’s WhoStrathmore's Who's Who publishes an annual two thousand page hard cover biographical registry, honoring successful individuals in the fields of Business, the Arts and Sciences, Law, Engineering and Government. Based on one's position and lifetime of accomplishments, we honor professional men and women in all academic areas and professions. Inclusion is limited to individuals who have demonstrated leadership and achievement in their occupation, industry or profession. Click here to view the list of recent Press Releases from Strathmore Who's Who
News Article | May 8, 2017
CIOs, CISOs, VPs and Heads of IT from multiple healthcare verticals - including pharmaceuticals, life sciences, hospitals, health insurance organizations, and medical device companies - will gather for an exclusive two-day information-sharing, benchmarking, and networking event. At the Exchange, attendees will explore the latest topics in healthcare mobility, from wearables and security to enterprise apps and IoT. "Mobility is not just desired, but necessary in today's healthcare environment," said Dorene Rettas, Head of Enterprise Mobility Exchange, U.S. "The demand from clinicians and patients to have immediate and secure access to information is being heard loud and clear, yet with HIPAA requirements and compliance laws, it's not an easy task. We've created a meeting format that allows senior-level IT execs to come together to discuss their greatest challenges, address the growing demands placed upon them for mobility, and learn about solutions and support in the market." The Exchange will feature a mix of talented IT thought leaders poised to share their insight and expertise. One such industry expert is Aetna's Director of Software and Mobile Security, Brian Heemsoth, who will speak on the importance of protecting the enterprise while expanding the company's mobile initiatives. New York Presbyterian Hospital's Director of IT Innovation, Shauna Coyne will address how to evolve mobility as the patient's healthcare needs continue to transform, and the importance of digitizing a paper-based organization. In his analyst session titled "Communication is Key," VDC Research Vice President David Krebs will explain how to secure messaging and communications while satisfying governance. These and other presentations will round out an agenda packed with think tanks, round table discussions, networking activities, and meetings with on-site solution providers. Enterprise Mobility Exchange is an online community for business leaders seeking to leverage mobile technology and services to improve operational efficiency, increase customer acquisition, and drive profits. EME's multi-pronged approach provides industry news and expert commentary along with invitation-only events for high-level, global mobility professionals. These events bring together senior IT decision-makers from all industries. Learn more about what's happening in the industry by staying connected with the company's weekly newsletter here. To attend or sponsor Enterprise Mobility Exchange: Healthcare, contact Dorene Rettas at Dorene.Rettas@EnterpriseMobilityExchange.com or by calling +1-973-867-7744.
News Article | May 4, 2017
The May 15th issue of Life & Style magazine, on news stands now, features two of the country’s most respected facial plastic surgeons, Dr. Ben Talei and Dr. Ben Stong. These leading plastic surgeons discuss the considerable benefits of cosmetic surgery after cancer treatment. The article highlights the story of Angie Everhart, a popular cover model who turned to Dr. Talei for facial plastic surgery after her thyroid cancer recovery. As a teen, Everhart became a cover model for fashion magazines such as Elle and Glamour. She went on to appear in several Sports Illustrated swimsuit issues as well as Playboy magazine. After battling thyroid cancer in 2013, Everhart sought Dr. Talei’s expertise to counteract the facial aging effects of her cancer and the radiation treatment it demanded. With her cancer gone, Angie Everhart simply wanted to look as good as she felt, a common desire in patients who choose facial plastic surgery. Dr. Ben Talei, Director of the Beverly Hills Center for Plastic & Laser Surgery, was able to help Everhart by performing one of his specialties in cosmetic surgery, the AuraLyft. The AuraLyft is a modified facelift pioneered by Dr. Talei, where incisions are made under the muscles of the face, not just the skin. It can be performed painlessly using only local anesthesia, without the need for a general anesthetic. Everhart is thrilled with the results, stating in the Life & Style article “I look refreshed – like I’ve been to a spa!” Dr. Benjamin Stong of Kalos Facial Plastic Surgery in Atlanta also comments on Everhart’s plastic surgery in the Life & Style magazine story, “With Dr. Talei’s facelift surgery the results are absolutely natural and there is no need for ancillary procedures. The face is never made to look pulled or stretched. It’s beyond impressive.” Dr. Stong is a world-class facial plastic surgeon with highly esteemed training, experience and recognition in his field. He performs an extended, mini deep plane facelift in his own practice, using a technique that aligns very closely with the AuraLyft and produces the same unrivaled results. “Plastic surgery after cancer treatment can be the final catalyst to helping patients physically and emotionally overcome such a difficult stage in their lives,” says Dr. Ben Talei. “It’s very fulfilling to be able to positively contribute to that process.” About Dr. Ben Talei and Beverly Hills Center of Plastic and Laser Surgery: A native of California, Dr. Benjamin Talei graduated from the University of California, Los Angeles with a degree in Physiological Sciences. He received his medical degree at the University of California, San Diego School of Medicine. Dr. Talei went on to complete his residency training in Head and Neck Surgery at Columbia University and Cornell University Medical Centers, New York Presbyterian Hospital. Following his residency program, Dr. Talei became one of the only surgeons in the country to complete two separate fellowships in Facial & Plastic and Reconstructive Surgery including a fellowship at the Vascular Birthmark Institute of New York. In addition, Dr. Talei is a respected author, speaker and humanitarian. About Dr. Benjamin Stong and Kalos Facial Plastic Surgery, LLC: Owner and facial plastic surgeon, Dr. Benjamin Stong is dual board certified in Head and Neck Surgery and Facial Plastic and Reconstructive Surgery. He completed his fellowship under one of the most nationally renowned plastic surgeons, Dr. Andrew Jacono in New York. He has combined such a reputable level of training with his own proven experience and talent to bring patients of Atlanta outstanding results in all aspects of surgical and non-surgical cosmetic surgery. In his career thus far, Dr. Stong has earned high prestige in his field publishing multiple journal articles and book chapters over his career. He is also a Castle Connolly Top Doctors award for consecutive years. Dr. Stong also specializes in hair transplantation as well as the most innovative treatments in facial rejuvenation at The K Spa in Atlanta. For additional information on Dr. Talei and the Beverly Hills Center for Plastic and Laser Surgery please visit beverlyhillscenter.com or call (310) 288-0641. For additional information on Dr. Stong and Kalos Facial Plastic Surgery please visit http://www.kalos-plasticsurgery.com or call 404-963-6665.
News Article | May 4, 2017
LIVONIA, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, will host a key opinion leader (KOL) lunch to discuss the evolving nonalcoholic steatohepatitis (NASH) landscape in New York City on Tuesday, May 9 from 12:00pm - 1:30pm Eastern Time. The meeting will feature a presentation by key opinion leader David E. Cohen, MD, PhD (Weill Cornell), who will discuss the disease, evolving evaluation and clinical trial endpoints, and the current and investigational therapies for the treatment of nonalcoholic steatohepatitis (NASH). Dr. Cohen will be available to answer questions following the lunch. Gemphire's management team will also provide an overview of the Company’s ongoing clinical development work and commercial opportunity in cardiometabolic diseases focused on dyslipidemia and NASH with its lead drug candidate gemcabene. Gemcabene is a first-in-class, once-daily oral pill with the potential to be used as an adjunctive therapy to further reduce LDL-C (cholesterol), hsCRP (inflammation), and TGs (fat), while increasing insulin sensitization especially in diabetic and obese (‘diabesity’) patients which make up a large portion of the NASH population. David E. Cohen, MD, PhD is the Chief of the Division of Gastroenterology and Hepatology and the Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medical College. He is also the Editor-in-Chief of Hepatology. In addition, Dr. Cohen is the co-director of the Center for Advanced Digestive Care at Weill Cornell Medical College and New York Presbyterian Hospital. Dr. Cohen has served as a member of the NIH Hepatobiliary Pathophysiology Study Section and as Chair of the American Heart Association Lipoprotein and Lipid Metabolism Study Section, National Chapter. A member of the American Society for Clinical Investigation (ASCI) and the Interurban Clinical Club, Dr. Cohen is an internationally renowned physician-scientist with a major interest in the molecular regulation of hepatic lipid and glucose metabolism. The Cohen Laboratory has focused on the molecular regulation of nutrient metabolism and energy homeostasis by membrane lipids. Dr. Cohen’s research has been published in American Journal of Physiology, Journal of Lipid Research, Journal of Biological Chemistry, Hepatology, Gene, and Biochemistry, among others. He is also the author of numerous book chapters. This lunch event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com. A live and archived webcast of the event, with slides, will be available at on the investors section of the Company’s website at www.gemphire.com and http://lifesci.rampard.com/20170509/reg.jsp. About Gemcabene Gemphire’s product candidate, gemcabene (CI-1027), is a first-in-class, once-daily, oral therapy that may be suitable for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statins. Gemcabene's mechanism of action is designed to enhance the clearance of very low-density lipoproteins (VLDLs) in the plasma and inhibit the production of cholesterol and triglycerides in the liver. The combined effect for these mechanisms has been clinically observed to result in a reduction of plasma VLDL-C, LDL-C, and triglycerides. In addition, gemcabene has been shown to markedly lower C-reactive protein and improve insulin sensitization. Gemcabene is liver-directed and reduces apoC-III mRNA and plasma levels. Gemcabene also reduces acetyl-CoA carboxylase (ACC) and CCR2/CCR5 receptor mRNA levels, which may have applications in non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD). Gemcabene has demonstrated proof of concept efficacy in the STAM™ model for NASH developed at SMC Laboratories in Tokyo, Japan. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in 895 subjects across 18 Phase 1 and Phase 2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability. About Gemphire Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has 3 clinical trials ongoing for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH in second half of 2017. Please visit www.gemphire.com for more information. Forward Looking Statements Any statements in this press release about Gemphire’s future expectations, plans and prospects, including statements about Gemphire’s financial prospects, future operations and sufficiency of funds for future operations, clinical development of Gemphire’s product candidate, expectations regarding future clinical trials and future expectations and plans and prospects for Gemphire, expectations regarding operating expenses and cash used in operations, and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "potential," "will," "would," "could," "should," "continue," “scheduled” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the success and timing of Gemphire’s regulatory submissions and pre-clinical and clinical trials; regulatory requirements or developments; changes to Gemphire’s clinical trial designs and regulatory pathways; changes in Gemphire’s capital resource requirements; Gemphire’s ability to obtain additional financing; Gemphire’s ability to successfully market and distribute its product candidate, if approved; Gemphire’s ability to obtain and maintain its intellectual property protection; and other factors discussed in the "Risk Factors" section of Gemphire’s Annual Report on Form 10-K for the year ended December 31, 2016, and in other filings Gemphire makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Gemphire’s views as of the date hereof. Gemphire anticipates that subsequent events and developments will cause Gemphire’s views to change. However, while Gemphire may elect to update these forward-looking statements at some point in the future, Gemphire specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Gemphire’s views as of any date subsequent to the date hereof.
News Article | May 4, 2017
CAEL-101 is in development by Fortress subsidiary Caelum Biosciences Phase 2 study planned for the first half of 2018 NEW YORK, May 04, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that study sponsor Columbia University (“Columbia”) has dosed the final patient in the Phase 1b clinical trial of CAEL-101, in development by Fortress subsidiary Caelum Biosciences, Inc. (“Caelum”) for the treatment of amyloid light chain (“AL”) amyloidosis. Caelum expects to readout preliminary Phase 1b data mid-2017, and full data by the end of the year. Michael Spector, Chief Executive Officer of Caelum, said, “The dosing of the final patient in our Phase 1 program is a key milestone for Caelum. CAEL-101 has the potential to provide an improved treatment option for people suffering from AL amyloidosis, a rare and fatal disease that lacks adequate therapeutic options. We look forward to presenting trial data later this year, and to initiating a Phase 2 study in the first half of 2018.” The Phase 1a/1b study (ClinicalTrials.gov Identifier: NCT02245867) is examining the tolerance, safety, pharmacokinetics and possible clinical benefit of CAEL-101, a chimeric fibril‐reactive monoclonal antibody (mAb), in patients with AL amyloidosis. CAEL-101 was administered to patients through a single intravenous infusion in the Phase 1a, and one weekly infusion for four weeks during the Phase 1b. The first patient received the starting dose and, if tolerated, the following patients received progressively higher doses. When trial investigators reached the maximum tolerated dose without toxicity, investigators enrolled another six patients to receive the same dose. Interim Phase 1a/1b data presented by Columbia at the American Society of Hematology’s (ASH) 58th Annual Meeting demonstrated that CAEL‐101 is safe and well-tolerated with no drug‐related adverse events or dose‐limiting toxicity up to 500mg/m2. A single infusion of CAEL‐101, or one weekly infusion for four weeks, provided early and sustained organ response in cardiac, renal, gastrointestinal, skin and soft tissue. Interim clinical efficacy data showed that CAEL‐101 promoted amyloid resolution in 67 percent of patients (63 percent in Phase 1a; 70 percent in Phase 1b). Suzanne Lentzsch, M.D., Ph.D., Professor of Medicine at Columbia University Medical Center, College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital, and principal investigator for the Phase 1a/1b study, said, “Standard-of-care chemotherapy is directed toward eliminating plasma cells that produce abnormal proteins, but does not adequately address new and existing amyloid build-up in organs, which can lead to organ failure and even death. CAEL-101 is specifically designed to bind to misfolded proteins and promote resolution. We look forward to translating the compelling biomarker results seen in the Phase 1a/1b to-date, in which CAEL-101 demonstrated sustained organ response after a single dose, into further clinical benefit and positive patient outcomes.” About AL Amyloidosis AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded amyloid proteins produced by plasma cells cause buildup in and around tissues, nerves and organs, gradually affecting their function. This can cause progressive and widespread organ damage, and high mortality rates. About Caelum Biosciences Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech (NASDAQ:FBIO) Company, is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. Caelum’s lead asset, CAEL-101 (11-14F), is a novel antibody in Phase 1b clinical trials for the treatment of patients with amyloid light chain (“AL”) amyloidosis. Interim Phase 1a/1b data presented at the American Society of Hematology’s 58th Annual Meeting in December 2016 support CAEL-101’s potential to be a safe and well-tolerated therapy that promotes amyloid resolution. CAEL-101 has received Orphan Drug Designation from the U.S. Food and Drug Administration as a therapeutic agent for patients with AL amyloidosis, and as a radio-imaging agent in amyloidosis. For more information, visit www.caelumbio.com. About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.